Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Norikazu MasudaHiroko BandoTakashi YamanakaTakayuki KadoyaMasato TakahashiShigenori E NagaiShoichiro OhtaniTomoyuki ArugaEiji SuzukiYuichiro KikawaHiroyuki YasojimaHiroi KasaiHiroshi IshiguroHidetaka KawabataSatoshi MoritaHironori HagaTatsuki R KataokaRyuji UozumiShinji OhnoMasakazu ToiPublished in: Breast cancer research and treatment (2021)
The study has been registered with the University Hospital Medical Information Network Clinical Trials Registry ( http://www.umin.ac.jp/ctr/index-j.htm ) with unique trial number UMIN000023162. The Japan Breast Cancer Research Group trial number is JBCRG-22.
Keyphrases
- phase ii
- clinical trial
- neoadjuvant chemotherapy
- double blind
- open label
- phase iii
- placebo controlled
- dna repair
- locally advanced
- lymph node
- study protocol
- dna damage
- sentinel lymph node
- healthcare
- squamous cell carcinoma
- randomized controlled trial
- cross sectional
- replacement therapy
- radiation therapy
- oxidative stress
- young adults
- smoking cessation